NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

David L. Porter, Edwin P. Alyea, Joseph H. Antin, Marcos DeLima, Eli Estey, J. H Frederik Falkenburg, Nancy Hardy, Nicolaus Kroeger, Jose Leis, John Levine, David G. Maloney, Karl Peggs, Jacob M. Rowe, Alan S. Wayne, Sergio Giralt, Michael R. Bishop, Koen van Besien

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

Original languageEnglish (US)
Pages (from-to)1467-1503
Number of pages37
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Hematopoietic Stem Cell Transplantation
Secondary Prevention
Education
Recurrence
Therapeutics
Hematologic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Monoclonal Antibodies
Tissue Donors
Lymphocytes
Transplants
Drug Therapy
Research

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Donor lymphocyte infusion
  • Treatment

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. / Porter, David L.; Alyea, Edwin P.; Antin, Joseph H.; DeLima, Marcos; Estey, Eli; Falkenburg, J. H Frederik; Hardy, Nancy; Kroeger, Nicolaus; Leis, Jose; Levine, John; Maloney, David G.; Peggs, Karl; Rowe, Jacob M.; Wayne, Alan S.; Giralt, Sergio; Bishop, Michael R.; van Besien, Koen.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 11, 11.2010, p. 1467-1503.

Research output: Contribution to journalArticle

Porter, DL, Alyea, EP, Antin, JH, DeLima, M, Estey, E, Falkenburg, JHF, Hardy, N, Kroeger, N, Leis, J, Levine, J, Maloney, DG, Peggs, K, Rowe, JM, Wayne, AS, Giralt, S, Bishop, MR & van Besien, K 2010, 'NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 16, no. 11, pp. 1467-1503. https://doi.org/10.1016/j.bbmt.2010.08.001
Porter, David L. ; Alyea, Edwin P. ; Antin, Joseph H. ; DeLima, Marcos ; Estey, Eli ; Falkenburg, J. H Frederik ; Hardy, Nancy ; Kroeger, Nicolaus ; Leis, Jose ; Levine, John ; Maloney, David G. ; Peggs, Karl ; Rowe, Jacob M. ; Wayne, Alan S. ; Giralt, Sergio ; Bishop, Michael R. ; van Besien, Koen. / NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 11. pp. 1467-1503.
@article{fa1cbfb6c26a4ea481e03f262e69c1fb,
title = "NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Donor lymphocyte infusion, Treatment",
author = "Porter, {David L.} and Alyea, {Edwin P.} and Antin, {Joseph H.} and Marcos DeLima and Eli Estey and Falkenburg, {J. H Frederik} and Nancy Hardy and Nicolaus Kroeger and Jose Leis and John Levine and Maloney, {David G.} and Karl Peggs and Rowe, {Jacob M.} and Wayne, {Alan S.} and Sergio Giralt and Bishop, {Michael R.} and {van Besien}, Koen",
year = "2010",
month = "11",
doi = "10.1016/j.bbmt.2010.08.001",
language = "English (US)",
volume = "16",
pages = "1467--1503",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

T2 - Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

AU - Porter, David L.

AU - Alyea, Edwin P.

AU - Antin, Joseph H.

AU - DeLima, Marcos

AU - Estey, Eli

AU - Falkenburg, J. H Frederik

AU - Hardy, Nancy

AU - Kroeger, Nicolaus

AU - Leis, Jose

AU - Levine, John

AU - Maloney, David G.

AU - Peggs, Karl

AU - Rowe, Jacob M.

AU - Wayne, Alan S.

AU - Giralt, Sergio

AU - Bishop, Michael R.

AU - van Besien, Koen

PY - 2010/11

Y1 - 2010/11

N2 - Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

AB - Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Donor lymphocyte infusion

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77957754106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957754106&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.08.001

DO - 10.1016/j.bbmt.2010.08.001

M3 - Article

C2 - 20699125

AN - SCOPUS:77957754106

VL - 16

SP - 1467

EP - 1503

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -